Assembly Biosciences Initiates Phase 2a Trial for HBV Core Inhibitor

Assembly Biosciences Initiates Phase 2a Trial for HBV Core Inhibitor (Healio)

UF Innovate | Sid Martin Biotech alumni company Assembly Bioscience announced the initiation of two randomized control phase 2a trials for ABI-H0731, the company’s lead hepatitis B core inhibitor, according to a press release.

ABI-H0731 previously demonstrated potent antiviral activity in a phase 1b trial, the results of which were presented at the International Liver Congress 2018 in Paris.

“These studies will provide data on the potential of ABI-H0731 to increase cure rates by suppressing viral replication to a greater degree than is currently achieved with standard nucleos(t)ide therapy alone,” Uri Lopatin, MD, chief medical officer of Assembly Biosciences, said in the release. “Such a result would support that clinical cure of chronic HBV may be possible with a finite course of direct acting combination therapy.”

Learn more about Assembly Biosciences Initiates Phase 2a Trial for HBV Core Inhibitor.

X